Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04847596 · ClinicalTrials.gov registry record
A Multicenter Study to Assess Response to COVID-19 Vaccine in Multiple Sclerosis Participants Treated With Ofatumumab
A clinical trial, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- 25
- Enrollment target
NCT04847596: Completed study, sponsored by Novartis Pharmaceuticals.
NCT04847596 is a clinical trial that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 25 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04847596 has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- 25 participants
- Enrollment target
Study Summary
This is a single arm, pilot multicenter prospective study in up to 22 participants with relapsing multiple sclerosis. Patients screened for the study can either be scheduled for vaccine, have received a single vaccine with a scheduled second dose, or already completed full course (two dose) vaccination. Fully vaccinated participants must be able to complete immune assay No.1 ≥ 14 days after the second dose of vaccine
Primary Outcome
Achieving immune response as defined by a positive SARS-CoV-2 qualitative IgG antibody assay. (yes/no)
Interventions
- OTHER Ofatumumab
- OTHER Covid-19 vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2021-05-21 |
| Est. Completion | 2022-02-18 |
What the finished NCT04847596 record still lists
NCT04847596 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 25 participants, a relatively small participant target.
The record links to 0 conditions, and to 2 interventions - of which Ofatumumab is the first listed.
NCT04847596 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04847596 about?
NCT04847596 is a clinical study titled "A Multicenter Study to Assess Response to COVID-19 Vaccine in Multiple Sclerosis Participants Treated With Ofatumumab". This is a single arm, pilot multicenter prospective study in up to 22 participants with relapsing multiple sclerosis. Patients screened for the study can either be scheduled for vaccine, have received a single vaccine with a scheduled second dose, or already completed full course (two dose) vaccinat...
What is the current status of trial NCT04847596?
This trial is currently completed. The enrollment target is 25 participants. The study started on 2021-05-21. Estimated completion is 2022-02-18.
What interventions are being tested in trial NCT04847596?
The interventions under investigation include: Ofatumumab (OTHER), Covid-19 vaccine (OTHER).
Who is sponsoring clinical trial NCT04847596?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI